FDA-NDA019835
Document details
Summary
CETIRIZINE HYDROCHLORIDE, marketed as ZYRTEC HIVES, is an oral drug and will be billed under Medicare Part D. Given that it is not an injectable drug, no J-code will be assigned, and typical reimburseNewly approved ZYRTEC HIVES impacts Medicare Part D billing.
Affected specialty
Dermatology alerts →Source document
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019835CLV Intelligence summarizes publicly available federal publications. Not affiliated with or endorsed by any government agency.
Related alerts
4Policy FDA-BLA761262 · Dermatology
SKYRIZI (risankizumab-rzaa) is an injectable drug approved for use under Medicare Part B, likely leading to the assignment of a new J-code for billing purposes. As an orphan drug in the interleukin-23
View alertPolicy FDA-BLA761105 · Dermatology
SKYRIZI (Risankizumab-rzaa), being an injectable drug approved under the BLA, is likely to be assigned a J-code for Medicare billing. Given its classification as an orphan drug and its high cost, pass
View alertPolicy FDA-NDA021951 · Dermatology
As ABSORICA (isotretinoin) is an oral drug, it will be billed under Medicare Part D. Given that it is a medication used for severe acne, prescribers should consider any prior authorizations or step th
View alertPolicy FDA-BLA761306 · Dermatology
EBGLYSS (LBRIKIZUMAB-LBKZ) will be billed under Part B as it is an injectable drug. Billing teams should confirm the specifics of the J-code upon the release of the FDA label.
View alert